DNLI · Denali Therapeutics Inc.
$21.09
-1.45% last session
End-of-day data · close of 2026-09-11
Market cap
$3B
Enterprise value
$3B
Trailing P/E
—
Forward P/E
-8.7
Dividend yield
—
Beta
1.00
Avg volume
2M
Employees
1K
Daily Change %
-1.45%
5 Days Change
-3.95%
10 Days Change
-8.02%
30 Days Change
-15.31%
60 Days Change
-19.18%
Month to Day Change
-8.02%
Year to Day Change
29.62%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — DNLI
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-08-25
Latest call per bank · past 12 months
UBS
Buy$34.00
+58.9% vs priceMorgan Stanley
Overweight$36.00
+68.2% vs priceDeutsche Bank
Buy$35.00
+63.6% vs priceGoldman Sachs
Buy$40.00
+86.9% vs priceJP Morgan
Overweight$26.00
+21.5% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-25 | B. Riley Securities | Maintains | Buy | $30.00 → $35.00 |
| 2026-08-07 | UBS | Maintains | Buy | $25.00 → $34.00 |
| 2026-07-23 | Morgan Stanley | Maintains | Overweight | $35.00 → $36.00 |
| 2026-07-16 | Deutsche Bank | Maintains | Buy | $31.00 → $35.00 |
| 2026-05-26 | Morgan Stanley | Maintains | Overweight | $40.00 → $35.00 |
| 2026-05-14 | Morgan Stanley | Maintains | Overweight | $42.00 → $40.00 |
| 2026-05-11 | BTIG | Reiterates | Buy | $39.00 |
| 2026-05-08 | Wedbush | Maintains | Outperform | $25.00 → $23.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 29 — oversold territory; selling pressure looks stretched.
- Price vs 50-day MA: Trading 12.4% below the 50-day MA ($24.09).
- Price vs 200-day MA: Trading 0.8% above the 200-day MA ($20.92).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.35) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($12.75) and high ($27.21).
DNLI Price Chart
Loading chart for DNLI…
Fundamentals
About Denali Therapeutics Inc.
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$131B 13.5% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$80B 3.2% YTD
ARGX
argenx SE
$62B 17.0% YTD
MRNA
Moderna, Inc.
$57B 363.3% YTD
RVMD
Revolution Medicines, Inc.
$44B 155.3% YTD
ONC
BeOne Medicines Ltd.
$39B 12.5% YTD
RPRX
Royalty Pharma plc
$34B 54.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$33B -37.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.